There are no differences in the effects of GHRH and GHRH analogs like sermorelin or GRF (1-29) when tesamorelin is used as a substitute for GHRH. Tesamorelin’s half-life is increased by adding trans-3-hexanoic acid to the medication. GHRH’s physiological function is preserved by tesamorelin, which has a longer half-life than CJC-1295 but fewer adverse effects than other GHRH-blocking compounds.
Lipodystrophy and Tesamorelin are two Related Conditions
For HIV-associated lipodystrophy, tesamorelin is primarily used to treat antiretroviral therapy-induced lipodystrophy. Both the abdomen and other parts of the body are affected by lipodystrophy. Protease inhibitors, which are widely prescribed, have a significant role in the etiology of lipodystrophy. However, the exact mechanism is not known.
Initially, patients with lipodystrophy relied on diet, exercise, and a small number of ineffectual drugs to address the condition. Finally, surgery was a last-ditch option that was often futile and difficult to do. It was only in 2010 that Tesamorelin was explicitly licensed to treat HIV-related lipodystrophy by the Food and Drug Administration. In this group, the medication lower body fat by approximately 20%. According to research, Tesamorelin seems to be four times more effective than all other treatments combined in reducing body fat.
Research on Tesamorelin in the Treatment of Cardiovascular Disease
An increased risk of cardiovascular disease (CVD) may be attributed to aberrant fat deposition in HIV patients and the activities of antiretroviral medicines themselves. After HAART, cardiovascular disease (CVD) prevention in HIV-positive patients is regarded as the most critical medical intervention for long-term well-being. Medical therapy in this group has traditionally relied on statins.
Tesamorelin peptide for sale has been shown in studies to lower triglyceride, total cholesterol, and non-HDL-C levels in HIV-positive individuals and lower lipodystrophy. Visceral adiposity is reduced by 15% with tesamorelin. Triglyceride levels are reduced by 50%.
Lipodystrophy is characterized by a buildup of ectopic fat that is often accompanied by inflammation. Cardiovascular disease is exacerbated by inflammation of any type. Cardiovascular disease (CVD) is related to an increased risk of visceral adipose tissue, liver fat, and epicardial fat. Tesamorelin reduces inflammation and the risk of cardiovascular disease by lowering ectopic fat accumulation.
HAART has been linked to a range of endocrine and metabolic issues, including growth hormone (GH) insufficiency. About one-third of HIV patients on HAART exhibit GH insufficiency due to changes in the pituitary gland that seem to be caused by the virus. Lipodystrophy is widespread in people with HIV, and Tesamorelin is an effective therapy for the condition. HIV-positive subjects should be administered tesamorelin rather than exogenous injections to boost GH levels.
Tesamorelin for Damage to Nerves in the Periphery
Damage to the peripheral nerves may result from various causes, including trauma, diabetes, and even surgery. Consequently, it may cause significant issues with both motor and sensory function in the afflicted region, but there is no cure since nerve cells are notoriously hard to replace. However, therapy based on growth hormone modification has been shown to alleviate peripheral nerve damage and boost recovery speed and extent. Because the FDA has previously approved it, tesamorelin is now the most likely choice for such an intervention.